At a glance
ClinicalIndex Comparison RecordN/ACompleted· 68 enrolled
Drug / intervention
Erchonia Scanner device (GLS) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia Scanner Device (GLS) Green Diode on Reducing the Appearance of Cellulite Clinical Study Protocol.
In Brief
A clinical study evaluating Erchonia Scanner device (GLS) and Placebo device for Cellulite. Completed, enrolled 68 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether the application of green diode low level laser light therapy is effective in reducing the appearance of cellulite in the thighs and buttocks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCellulite
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
Primary CompletionSep 2012
First PostedOct 2012
TodayJul 2026
First PostedOct 8, 2012
Enrollment StartOct 1, 2009
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.7 years ago
Interventions
Erchonia Scanner device (GLS)device
The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
Placebo devicedevice
Inactive Erchonia GLS.